1
|
da Fonseca IIM, Nagamine MK, Gentile LB, Nishiya AT, da Fonseca JM, de Oliveira Massoco C, Ward JM, Liu S, Leppla SH, Dagli MLZ. Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study. Vet Res Commun 2024; 48:2407-2428. [PMID: 38805149 DOI: 10.1007/s11259-024-10400-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Accepted: 04/29/2024] [Indexed: 05/29/2024]
Abstract
Mammary tumors are the most frequent type of neoplasms in intact female dogs. New therapies that target neoplastic cells without affecting normal cells are highly sought. The Bacillus anthracis toxin has been reengineered to target tumor cells that express urokinase plasminogen activators and metalloproteinases. In previous studies carried out in our laboratory, the reengineered anthrax toxin had inhibitory effects on canine oral mucosal melanoma and canine osteosarcoma cells. In this study, five canine neoplastic epithelial cell lines (four adenocarcinomas and one adenoma) and one non-neoplastic canine mammary epithelial cell line were treated with different concentrations of reengineered anthrax toxin components. Cell viability was quantified using an MTT assay and half-maximal inhibitory concentration (IC50) values. Cell lines were considered sensitive when the IC50 was lower than 5000 ng/ml. One canine mammary adenocarcinoma cell line and one mammary adenoma cell line showed significantly decreased viability after treatment, whereas the non-neoplastic cell line was resistant. We conclude that the reengineered anthrax toxin may be considered a targeted therapy for canine mammary neoplasms while preserving normal canine mammary epithelial cells.
Collapse
Affiliation(s)
- Ivone Izabel Mackowiak da Fonseca
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil
| | - Márcia Kazumi Nagamine
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil
| | - Luciana Boffoni Gentile
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil
| | - Adriana Tomoko Nishiya
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil
| | - Jonathan Mackowiak da Fonseca
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil
| | - Cristina de Oliveira Massoco
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil
| | | | - Shihui Liu
- Aging Institute and Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15261, USA
| | - Stephen Howard Leppla
- Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Maria Lucia Zaidan Dagli
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil.
| |
Collapse
|
2
|
Prognostic significance of the urokinase plasminogen activator system in tissue and serum of dogs with appendicular osteosarcoma. PLoS One 2022; 17:e0273811. [PMID: 36174075 PMCID: PMC9522282 DOI: 10.1371/journal.pone.0273811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Accepted: 08/15/2022] [Indexed: 11/25/2022] Open
Abstract
Urokinase plasminogen activator (uPA) and its receptor uPAR promote cancer invasion and metastasis and are emerging therapeutic targets in both human and canine malignancies. While their clinical significance is well-characterized in multiple human tumor types, studies investigating their roles in osteosarcoma are lacking. The objectives of this study were to characterize serum and tissue uPA/uPAR expression in dogs with osteosarcoma and assess the prognostic significance. Serum samples and a tissue microarray of canine appendicular osteosarcoma were analyzed for uPA and uPAR expression by ELISA (n = 49) and immunohistochemistry (n = 38), respectively. Serum uPA activity was also measured by a chromogenic assay (n = 25). Survival analysis was performed by Kaplan-Meier survival analysis, log rank test, and Cox regression analysis. Serum uPA level was significantly higher in dogs with osteosarcoma than clinically healthy control dogs (median 1905 vs 1440 pg/ml, p = 0.008). The majority of canine osteosarcoma tissues expressed uPA (75.9%) or uPAR (77.6%), with 70.7% dual-positivity, indicating autocrine/paracrine activation of the pathway. Survival analysis revealed shorter progression free survival (PFS) in dogs with high serum uPA level in a discovery cohort (n = 29; median PFS 94 vs 266 days, p = 0.003) but not in a validation cohort (n = 23; median PFS 167 vs 490 days, p = 0.16). The difference was significant when both cohorts were combined (n = 49; median PFS 128 vs 266 days, p = 0.003). Serum uPAR and tissue uPA/uPAR levels were not prognostic. In Cox multivariate analysis, high serum uPA level and activity were both associated with poor prognosis, independent of serum ALP, tumor location, and peripheral lymphocyte/monocyte counts. These results indicate high utilization of the uPA pathway and association with disease progression in canine osteosarcoma. Further study involving prospective evaluation to confirm the prognostic significance is warranted. The high prevalence of tissue uPA and uPAR expression suggests the uPA system as a potential therapeutic target in canine osteosarcoma.
Collapse
|
3
|
Mackowiak da Fonseca J, Mackowiak da Fonseca II, Nagamine MK, Massoco CDO, Nishiya AT, Ward JM, Liu S, Leppla SH, Bugge TH, Dagli MLZ. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine and Human Osteosarcoma Cells. Toxins (Basel) 2020; 12:toxins12100614. [PMID: 32987941 PMCID: PMC7601267 DOI: 10.3390/toxins12100614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 09/12/2020] [Accepted: 09/14/2020] [Indexed: 12/03/2022] Open
Abstract
Canine and human osteosarcomas (OSA) share similarities. Novel therapies are necessary for these tumours. The Bacillus anthracis toxin was reengineered to target and kill cells with high expressions of matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Since canine OSA express MMPs and uPA, we assessed whether the reengineered toxin could show efficacy against these tumours. Two OSA cell lines (canine D17 and human MG63) and a non-neoplastic canine osteoblastic cell line (COBS) were used. Cells were treated with different concentrations of the reengineered anthrax toxin and cell viability was quantified using MTT assay. The cell cycle, apoptosis, and necrosis were analysed by flow cytometry. The wound-healing assay was performed to quantify the migration capacity of treated cells. D17 and MG63 cells had significantly decreased viability after 24 h of treatment. Cell cycle analysis revealed that OSA cells underwent apoptosis when treated with the toxin, whereas COBS cells arrested in the G1 phase. The wound-healing assay showed that D17 and MG63 cells had a significantly reduced migration capacity after treatment. These results point for the first time towards the in vitro inhibitory effects of the reengineered anthrax toxin on OSA cells; this reengineered toxin could be further tested as a new therapy for OSA.
Collapse
Affiliation(s)
- Jonathan Mackowiak da Fonseca
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, Sao Paulo 05508-270, SP, Brazil; (J.M.d.F.); (I.I.M.d.F.); (M.K.N.); (C.d.O.M.); (A.T.N.)
| | - Ivone Izabel Mackowiak da Fonseca
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, Sao Paulo 05508-270, SP, Brazil; (J.M.d.F.); (I.I.M.d.F.); (M.K.N.); (C.d.O.M.); (A.T.N.)
| | - Marcia Kazumi Nagamine
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, Sao Paulo 05508-270, SP, Brazil; (J.M.d.F.); (I.I.M.d.F.); (M.K.N.); (C.d.O.M.); (A.T.N.)
| | - Cristina de Oliveira Massoco
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, Sao Paulo 05508-270, SP, Brazil; (J.M.d.F.); (I.I.M.d.F.); (M.K.N.); (C.d.O.M.); (A.T.N.)
| | - Adriana Tomoko Nishiya
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, Sao Paulo 05508-270, SP, Brazil; (J.M.d.F.); (I.I.M.d.F.); (M.K.N.); (C.d.O.M.); (A.T.N.)
| | | | - Shihui Liu
- Aging Institute and Division of Infectious Diseases, Department of Medicine, University of Pittsburg, Pittsburgh, PA 15261, USA;
| | - Stephen Howard Leppla
- Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA;
| | - Thomas Henrik Bugge
- Proteases & Tissue Remodeling Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD 20892, USA;
| | - Maria Lucia Zaidan Dagli
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, Sao Paulo 05508-270, SP, Brazil; (J.M.d.F.); (I.I.M.d.F.); (M.K.N.); (C.d.O.M.); (A.T.N.)
- Correspondence: ; Tel.: +55-11-30917712
| |
Collapse
|
4
|
Viegas C, de Matos AJ, Leite-Martins LR, Viegas I, Ferreira RRF, Gregório H, Santos AA. Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats. CANADIAN JOURNAL OF VETERINARY RESEARCH = REVUE CANADIENNE DE RECHERCHE VETERINAIRE 2020; 84:60-66. [PMID: 31949329 PMCID: PMC6923816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Accepted: 03/12/2019] [Indexed: 06/10/2023]
Abstract
The urokinase plasminogen activator system (uPAS) has been poorly investigated in veterinary oncology. The aim of this study was to determine uPA serum concentrations in healthy and oncologic cats to understand the potential value of uPA as a cancer biomarker. Serum samples were collected from 19 healthy cats and 18 cats with spontaneous malignant neoplasms and uPA was measured through a specific enzyme-linked immunosorbent assay kit. The differences between uPA values and their relation with intrinsic factors and clinicopathological parameters were analyzed using an analysis of variance (ANOVA) and independent t-test. The average serum concentration of uPA in cancerous cats (0.54 ± 0.22 ng/mL) differed from that of healthy cats (1.10 ± 1.16 ng/mL) but was not significantly influenced by cats' clinicopathological parameters or by the presence of metastases. This study describes, for the first time, the serum concentrations of uPA in cats and proposes directions for future studies to uncover the relevance of uPAS in feline carcinogenesis.
Collapse
Affiliation(s)
- Cláudia Viegas
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, Lisbon, Portugal (Viegas C, Viegas I); Animal Blood Bank, R. de João de Deus 741, Porto, Portugal (Ferreira); Department of Veterinary Clinics of the Biomedical Sciences Institute of Abel Salazar, University of Porto, R. Jorge Viterbo Ferreira 228, Porto, Portugal (de Matos, Leite-Martins, Santos); Animal Science and Study Centre/Food and Agrarian Sciences and Technologies Institute, P. Gomes Teixeira, Porto, Portugal (de Matos, Santos); Centro Hospitalar Veterinário, Porto, Portugal (Gregório)
| | - Augusto J de Matos
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, Lisbon, Portugal (Viegas C, Viegas I); Animal Blood Bank, R. de João de Deus 741, Porto, Portugal (Ferreira); Department of Veterinary Clinics of the Biomedical Sciences Institute of Abel Salazar, University of Porto, R. Jorge Viterbo Ferreira 228, Porto, Portugal (de Matos, Leite-Martins, Santos); Animal Science and Study Centre/Food and Agrarian Sciences and Technologies Institute, P. Gomes Teixeira, Porto, Portugal (de Matos, Santos); Centro Hospitalar Veterinário, Porto, Portugal (Gregório)
| | - Liliana R Leite-Martins
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, Lisbon, Portugal (Viegas C, Viegas I); Animal Blood Bank, R. de João de Deus 741, Porto, Portugal (Ferreira); Department of Veterinary Clinics of the Biomedical Sciences Institute of Abel Salazar, University of Porto, R. Jorge Viterbo Ferreira 228, Porto, Portugal (de Matos, Leite-Martins, Santos); Animal Science and Study Centre/Food and Agrarian Sciences and Technologies Institute, P. Gomes Teixeira, Porto, Portugal (de Matos, Santos); Centro Hospitalar Veterinário, Porto, Portugal (Gregório)
| | - Inês Viegas
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, Lisbon, Portugal (Viegas C, Viegas I); Animal Blood Bank, R. de João de Deus 741, Porto, Portugal (Ferreira); Department of Veterinary Clinics of the Biomedical Sciences Institute of Abel Salazar, University of Porto, R. Jorge Viterbo Ferreira 228, Porto, Portugal (de Matos, Leite-Martins, Santos); Animal Science and Study Centre/Food and Agrarian Sciences and Technologies Institute, P. Gomes Teixeira, Porto, Portugal (de Matos, Santos); Centro Hospitalar Veterinário, Porto, Portugal (Gregório)
| | - Rui R F Ferreira
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, Lisbon, Portugal (Viegas C, Viegas I); Animal Blood Bank, R. de João de Deus 741, Porto, Portugal (Ferreira); Department of Veterinary Clinics of the Biomedical Sciences Institute of Abel Salazar, University of Porto, R. Jorge Viterbo Ferreira 228, Porto, Portugal (de Matos, Leite-Martins, Santos); Animal Science and Study Centre/Food and Agrarian Sciences and Technologies Institute, P. Gomes Teixeira, Porto, Portugal (de Matos, Santos); Centro Hospitalar Veterinário, Porto, Portugal (Gregório)
| | - Hugo Gregório
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, Lisbon, Portugal (Viegas C, Viegas I); Animal Blood Bank, R. de João de Deus 741, Porto, Portugal (Ferreira); Department of Veterinary Clinics of the Biomedical Sciences Institute of Abel Salazar, University of Porto, R. Jorge Viterbo Ferreira 228, Porto, Portugal (de Matos, Leite-Martins, Santos); Animal Science and Study Centre/Food and Agrarian Sciences and Technologies Institute, P. Gomes Teixeira, Porto, Portugal (de Matos, Santos); Centro Hospitalar Veterinário, Porto, Portugal (Gregório)
| | - Andreia A Santos
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, Lisbon, Portugal (Viegas C, Viegas I); Animal Blood Bank, R. de João de Deus 741, Porto, Portugal (Ferreira); Department of Veterinary Clinics of the Biomedical Sciences Institute of Abel Salazar, University of Porto, R. Jorge Viterbo Ferreira 228, Porto, Portugal (de Matos, Leite-Martins, Santos); Animal Science and Study Centre/Food and Agrarian Sciences and Technologies Institute, P. Gomes Teixeira, Porto, Portugal (de Matos, Santos); Centro Hospitalar Veterinário, Porto, Portugal (Gregório)
| |
Collapse
|
5
|
Birkbeck R, Humm K, Cortellini S. A review of hyperfibrinolysis in cats and dogs. J Small Anim Pract 2019; 60:641-655. [PMID: 31608455 DOI: 10.1111/jsap.13068] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Revised: 08/21/2019] [Accepted: 08/21/2019] [Indexed: 12/14/2022]
Abstract
The fibrinolytic system is activated concurrently with coagulation; it regulates haemostasis and prevents thrombosis by restricting clot formation to the area of vascular injury and dismantling the clot as healing occurs. Dysregulation of the fibrinolytic system, which results in hyperfibrinolysis, may manifest as clinically important haemorrhage. Hyperfibrinolysis occurs in cats and dogs secondary to a variety of congenital and acquired disorders. Acquired disorders associated with hyperfibrinolysis, such as trauma, cavitary effusions, liver disease and Angiostrongylus vasorum infection, are commonly encountered in primary care practice. In addition, delayed haemorrhage reported in greyhounds following trauma and routine surgical procedures has been attributed to a hyperfibrinolytic disorder, although this has yet to be characterised. The diagnosis of hyperfibrinolysis is challenging and, until recently, has relied on techniques that are not readily available outside referral hospitals. With the recent development of point-of-care viscoelastic techniques, assessment of fibrinolysis is now possible in referral practice. This will provide the opportunity to target haemorrhage due to hyperfibrinolysis with antifibrinolytic drugs and thereby reduce associated morbidity and mortality. The fibrinolytic system and the conditions associated with increased fibrinolytic activity in cats and dogs are the focus of this review article. In addition, laboratory and point-of-care techniques for assessing hyperfibrinolysis and antifibrinolytic treatment for patients with haemorrhage are reviewed.
Collapse
Affiliation(s)
- R Birkbeck
- Department of Veterinary Clinical Sciences, The Royal Veterinary College, Hertfordshire, AL9 7TA, UK
| | - K Humm
- Department of Veterinary Clinical Sciences, The Royal Veterinary College, Hertfordshire, AL9 7TA, UK
| | - S Cortellini
- Department of Veterinary Clinical Sciences, The Royal Veterinary College, Hertfordshire, AL9 7TA, UK
| |
Collapse
|